Dementia management has evolved with drugs such as lecanemab, shifting management from palliative care to early diagnosis and intervention. However, the administration of these drugs presents challenges owing to the invasiveness, high cost and limited availability of amyloid-PET and cerebrospinal fluid tests for guiding drug administration. Our manuscript explores the potential of less invasive blood biomarkers as a diagnostic method, with a cost-effectiveness analysis and a comparison with traditional tests. Our findings suggest that blood biomarkers are a cost-effective alternative, but with lower accuracy, indicating the need for multiple specific biomarkers for precision. This underscores the importance of future research on new blood biomarkers and their clinical efficacy.

中文翻译：

---

阿尔茨海默病诊断中血液生物标志物与常规检测的成本效益比较

痴呆症的治疗随着乐卡奈单抗（lecanemab）等药物的发展而不断发展，将治疗从姑息治疗转向早期诊断和干预。然而，由于淀粉样蛋白-PET 和脑脊液测试用于指导药物给药的侵入性、高成本和可用性有限，这些药物的给药面临着挑战。我们的手稿探讨了侵入性较小的血液生物标志物作为诊断方法的潜力，并进行了成本效益分析并与传统测试进行了比较。我们的研究结果表明，血液生物标志物是一种具有成本效益的替代方案，但准确性较低，表明需要多种特定生物标志物来提高精度。这强调了未来研究新血液生物标志物及其临床功效的重要性。